thyroxine has been researched along with Melanoma in 18 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "3,3',5-L-triiodothyronine (T3) can inhibit tyrosinase activity in B16/C3 melanoma cells in culture and block the induction of that enzyme by imidazole (Endocrinol." | 7.67 | 3,3',5-L-triiodothyronine but not L-thyroxine can block the induction of tyrosinase by imidazole in cultured B16 melanoma cells. ( Kline, EL; Smith, TJ, 1988) |
| " In two independent experiments oral propylthiouracil (PTU) was used to induce hypothyroidism (n=9), thyroxine to induce hyperthyroidism (n=11) and mice given plain water served as control (n=8)." | 3.81 | Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( Ashur-Fabian, O; Cohen, K; Davis, PJ; Ellis, M; Fabian, I; Fabian, ID; Hercbergs, A; Lin, HY; Rosner, M; Shinderman Maman, E; Vishnevskia-Dai, V; Zloto, O, 2015) |
| "3,3',5-L-triiodothyronine (T3) can inhibit tyrosinase activity in B16/C3 melanoma cells in culture and block the induction of that enzyme by imidazole (Endocrinol." | 3.67 | 3,3',5-L-triiodothyronine but not L-thyroxine can block the induction of tyrosinase by imidazole in cultured B16 melanoma cells. ( Kline, EL; Smith, TJ, 1988) |
| "Hypophysitis is one of the most common endocrine abnormalities." | 1.62 | Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. ( Greener, V; Lai, ZM; Larkin, J; Morganstein, DL; Siddiqui, MS; Spain, L; Turajlic, S, 2021) |
| "Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs)." | 1.51 | Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. ( Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A, 2019) |
| " Levothyroxine dosing required doubling in three patients with a known history of hypothyroidism." | 1.46 | Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. ( Bornschlegl, S; Delivanis, DA; Dietz, AB; Gustafson, MP; Kottschade, L; Merten, MM; Ryder, M; Withers, S, 2017) |
| " We report a case highlighting the occurrence of serious induced immune-related adverse events, which were attributed to pembrolizumab in a patient with metastatic melanoma who obtained a complete response (CR) after receiving pembrolizumab for a total of 6." | 1.46 | Risk of cumulative toxicity after complete melanoma response with pembrolizumab. ( Brown, MP; Faithfull, S; Hsieh, AH, 2017) |
| "The patient presented recurrences of metastatic skin nodules, lung and bone metastases, and died after a 3-year follow-up." | 1.29 | Cutaneous metastasis from follicular carcinoma of the thyroid gland. ( Bazex, J; Caron, P; Gorguet, B; Moreau-Cabarrot, A, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Siddiqui, MS | 1 |
| Lai, ZM | 1 |
| Spain, L | 1 |
| Greener, V | 1 |
| Turajlic, S | 1 |
| Larkin, J | 1 |
| Morganstein, DL | 1 |
| Yamauchi, I | 2 |
| Sakane, Y | 1 |
| Fukuda, Y | 1 |
| Fujii, T | 2 |
| Taura, D | 2 |
| Hirata, M | 1 |
| Hirota, K | 1 |
| Ueda, Y | 1 |
| Kanai, Y | 1 |
| Yamashita, Y | 1 |
| Kondo, E | 1 |
| Sone, M | 2 |
| Yasoda, A | 2 |
| Inagaki, N | 2 |
| Delivanis, DA | 1 |
| Gustafson, MP | 1 |
| Bornschlegl, S | 1 |
| Merten, MM | 1 |
| Kottschade, L | 1 |
| Withers, S | 1 |
| Dietz, AB | 1 |
| Ryder, M | 1 |
| Ansorge, C | 1 |
| Seufert, J | 1 |
| Meiss, F | 1 |
| von Bubnoff, D | 1 |
| Peiró, I | 1 |
| Palmero, R | 1 |
| Iglesias, P | 1 |
| Díez, JJ | 1 |
| Simó-Servat, A | 1 |
| Marín, JA | 1 |
| Jiménez, L | 1 |
| Domingo-Domenech, E | 1 |
| Mancho-Fora, N | 1 |
| Nadal, E | 1 |
| Villabona, C | 1 |
| Matsumoto, S | 1 |
| Sakamori, Y | 1 |
| Kim, YH | 1 |
| Nomura, M | 1 |
| Otsuka, A | 1 |
| Yamasaki, T | 1 |
| Saito, R | 1 |
| Kitamura, M | 1 |
| Kitawaki, T | 1 |
| Hishizawa, M | 1 |
| Kawaguchi-Sakita, N | 1 |
| Anderson, L | 1 |
| Bhatia, V | 1 |
| McElnea, E | 1 |
| Ní Mhéalóid, A | 1 |
| Moran, S | 1 |
| Kelly, R | 1 |
| Fulcher, T | 1 |
| Fabian, ID | 1 |
| Rosner, M | 1 |
| Fabian, I | 1 |
| Vishnevskia-Dai, V | 1 |
| Zloto, O | 1 |
| Shinderman Maman, E | 1 |
| Cohen, K | 1 |
| Ellis, M | 1 |
| Lin, HY | 1 |
| Hercbergs, A | 1 |
| Davis, PJ | 1 |
| Ashur-Fabian, O | 1 |
| Tanaka, R | 1 |
| Fujisawa, Y | 1 |
| Maruyama, H | 1 |
| Nakamura, Y | 1 |
| Yoshino, K | 1 |
| Ohtsuka, M | 1 |
| Fujimoto, M | 1 |
| Hsieh, AH | 1 |
| Faithfull, S | 1 |
| Brown, MP | 1 |
| STOLK, A | 1 |
| Larsson, B | 1 |
| Olander, K | 1 |
| Dencker, L | 1 |
| Holmqvist, L | 1 |
| Caron, P | 1 |
| Moreau-Cabarrot, A | 1 |
| Gorguet, B | 1 |
| Bazex, J | 1 |
| Guerra, L | 1 |
| Leiros, G | 1 |
| Sacerdote de Lustig, E | 1 |
| Phan, GQ | 1 |
| Attia, P | 1 |
| Steinberg, SM | 1 |
| White, DE | 1 |
| Rosenberg, SA | 1 |
| Smith, TJ | 1 |
| Kline, EL | 1 |
| Sadoff, L | 1 |
| Lusk, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma[NCT03918252] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-02 | Recruiting | ||
| Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.[NCT02259621] | Phase 2 | 45 participants (Anticipated) | Interventional | 2014-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 other studies available for thyroxine and Melanoma
| Article | Year |
|---|---|
Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Biomarkers; Female; Follow-Up Studies; Humans; Hy | 2021 |
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lung Neoplasm | 2017 |
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autoantibo | 2017 |
Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
Topics: Adult; Antineoplastic Agents, Immunological; Autoimmune Hypophysitis; Humans; Hydrocortisone; Hypopi | 2018 |
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Hodgkin D | 2019 |
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxygluco | 2019 |
Ipilimumab immune-related adverse reactions: a case report.
Topics: Antibodies, Monoclonal; Autoimmune Diseases; Female; Follow-Up Studies; Humans; Hydrocortisone; Hypo | 2013 |
Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab.
Topics: Aged; Antibodies, Monoclonal; Euthyroid Sick Syndromes; Exophthalmos; Female; Glucocorticoids; Grave | 2014 |
Low thyroid hormone levels improve survival in murine model for ocular melanoma.
Topics: Animals; Antithyroid Agents; Disease Models, Animal; Eye Neoplasms; Hyperthyroidism; Hypothyroidism; | 2015 |
Nivolumab-induced thyroid dysfunction.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Female; Hormone Replacement | 2016 |
Risk of cumulative toxicity after complete melanoma response with pembrolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Eruptions; Groin; Hormone Repla | 2017 |
Effect of thiouracil and thyroxine on development and growth of cutaneous melanoma in killifish hybrids.
Topics: Animals; Fundulidae; Growth and Development; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Expe | 1959 |
Accumulation of 125I-labelled thiouracil and propylthiouracil in murine melanotic melanomas.
Topics: Animals; Cells, Cultured; Iodine Radioisotopes; Melanoma; Mice; Mice, Inbred DBA; Neoplasms, Experim | 1982 |
Cutaneous metastasis from follicular carcinoma of the thyroid gland.
Topics: Adenocarcinoma, Follicular; Aged; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Melanoma; R | 1993 |
[The effect of L-thyroxine amino acid on human melanoma cell lines].
Topics: Cell Transformation, Neoplastic; Humans; Melanoma; Thyroxine; Tumor Cells, Cultured | 1993 |
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Inject | 2001 |
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Inject | 2001 |
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Inject | 2001 |
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Inject | 2001 |
3,3',5-L-triiodothyronine but not L-thyroxine can block the induction of tyrosinase by imidazole in cultured B16 melanoma cells.
Topics: Animals; Catechol Oxidase; Cells, Cultured; Enzyme Induction; Imidazoles; Melanoma; Mice; Monophenol | 1988 |
The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol T4 LH and testosterone in patients with advanced cancer.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Estrog | 1974 |